Algorithm used for dose reconstruction in workers. by Jonathan Côté (527819)

Algorithm used for the determination of the model parametric values. by Jonathan Côté (527819)

Overview of the algorithmic approach and its place in the hypothesis generation toolkit. by Braden T. Tierney (8822813)

Primary analysis of associations between POA exposure and neurodevelopmental disorders. by Emma N. Cleary (21103967)

Subjects:

Sensitivity analyses testing associations between dose of POA exposure and ADHD. by Emma N. Cleary (21103967)

Subjects:

Sensitivity analyses testing associations between dose of POA exposure and ASD. by Emma N. Cleary (21103967)

Subjects:

Data_Sheet_1_Bayesian Profile Regression to Deal With Multiple Highly Correlated Exposures and a Censored Survival Outcome. First Application in Ionizing Radiation Epidemiology.PDF by Marion Belloni (9566333)

“…Several groups of uranium miners with high risk and low risk of death by lung cancer were identified and characterized by specific exposure profiles. Interestingly, our case study illustrates a limit of MCMC algorithms to fit full Bayesian PRM models even if the updating schemes for the cluster labels incorporate label-switching moves. …”

Kaplan–Meier estimates of cumulative incidence for autism spectrum disorder by cumulative dose exposure level with 95% confidence intervals. by Emma N. Cleary (21103967)

Subjects:

Kaplan–Meier estimates of cumulative incidence for attention-deficit/hyperactivity disorder by cumulative dose exposure level with 95% confidence intervals. by Emma N. Cleary (21103967)

Subjects:

aLB cells show high encoding capacity across multiple environments. by Yijia Yan (49568)

Integrated epigenomic exposure signature discovery by Jared Schuetter (19531604)

Overview of GenomeTrackSig algorithm for profiling mutational signature activities across the genome. by Caitlin Timmons (14216474)

Key cohort characteristics. by Emma N. Cleary (21103967)

Subjects:

Image_1_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.JPEG by Kirsty E. Waddington (5754545)

Image_2_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.JPEG by Kirsty E. Waddington (5754545)

Data_Sheet_3_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.xlsx by Kirsty E. Waddington (5754545)

Data_Sheet_2_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.xlsx by Kirsty E. Waddington (5754545)

Data_Sheet_1_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.xlsx by Kirsty E. Waddington (5754545)

Data_Sheet_4_Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.pdf by Kirsty E. Waddington (5754545)

IS-Seq of a longitudinal series of stool samples from a human patient with a vancomycin resistant enterococcal infection. by Joshua M. Kirsch (16015889)